^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    umitrelimorgene autodencel (ITI-1000)

    i
    Associations
    News

    Trials

    Company:
    HLB Bio Group
    Drug class:
    Immunostimulant
    Related drugs:
    Associations
    News

    Trials

    Apply
    Basiliximab in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Undergoing Targeted Immunotherapy and Temozolomide-Caused Lymphopenia (REGULATe) (NCT00626483)
    Phase 1
    Gary Archer Ph.D.
    Completed
    Last update posted :
    03/09/2021
    Initiation :
    04/24/2007
    Primary completion :
    07/06/2016
    Completion :
    07/06/2016
    IL2RA • CD4 • IL7R • NCAM1 • ISG20
    |
    NCAM1 expression
    |
    temozolomide • Simulect (basiliximab) • umitrelimorgene autodencel (ITI-1000)